In vivo, IL-6 blockade reduces angiogenesis and recruitment of immunosuppressive myeloid-derived suppressor cells (MDSCs), slowing tumor regrowth after SBRT [25,30] (Figure 3). This evidence concerns the gene IL6 and neoplasm.